Exelixis Inc., of South San Francisco, said partner Ipsen SA, of Paris, received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for Cabometyx (cabozantinib) 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma.